ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026

Vienna, October 20, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that data supporting its targeted precision oncology portfolio were featured in three oral presentations and one e-poster at the European Association of Nuclear Medicine (EANM) 2026 Congress, held from October 17-21 in Vienna, Austria. The presentations further support ITM's late- and early-stage radiopharmaceutical pipeline, highlighting novel therapeutic and diagnostic candidates across Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), clear cell Renal Cell Carcinoma (ccRCC), and glioblastoma. “The data presented at EANM 2026 underscore the therapeutic potential of our deep targeted radiopharmaceutical pipeline, which leverages different targets, both established and novel radioisotopes, and addresses several difficult-to-treat oncology indications,” said Dr. Celine Wilke, chief medical officer of ITM. “Whether derived from ITM's Phase 3 COMPETE trial or through the valuable insights of independent, investigator-initiated research, this growing evidence base supports the continued development of these novel radiopharmaceuticals across cancers with significant unmet medical need.” Higher Cumulative Tumor Absorbed Dose of 177Lu-edotreotide is Associated with Improved Clinical Response in GEP-NETs Dr. Anthime Flaus of the Hospices Civils de Lyon in Bron, France gave an oral presentation featuring a late-stage dose-response analysis from ITM's Phase 3 COMPETE trial evaluating non-carrier-added (n.c.a.) 177Lu-edotreotide (ITM-11) in patients with Grade 1 or 2 GEP-NETs. The analysis assessed the relationship between tumor cumulative absorbed dose and treatment response in 106 evaluable patients who received 4 treatment cycles of ¹⁷⁷Lu-edotreotide therapy. Higher cumulative tumor absorbed doses were associated with a better Best Overall Response (BOR). The Objective Response Rate (ORR) increased from 12% in the lowest dose quartile (Q1) to 64% in the highest dose quartile (Q4), with three complete responses occurring in patients with a cumulative dose above 86.1 Gy (Q3 and Q4). Cumulative tumor absorbed dose and tumor type were the main predictors of response in multivariate logistic regression models. Lesion-level analysis also identified a statistically significant association between absorbed dose and response. "The dosimetry data from the COMPETE trial offer insights into how tumor absorbed dose correlates with objective response," said Dr. Anthime Flaus, study author and physician at the Hospices Civils de Lyon. "Understanding this dose-response relationship provides important evidence that could potentially support the development of more individualized radiopharmaceutical treatment approaches, with the goal of optimizing patient care and outcomes." Early-Stage Pipeline Data Presented at EANM 2026 The conference also highlighted promising clinical and translational data supporting the further development of other ITM pipeline candidates. These data, derived from independent trials and research initiated by investigators, offer valuable clinical insights to support the further development of ITM candidates currently in Phase 1 trials, including: Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, or CAIX peptide), an investigational diagnostic imaging agent for ccRCC; [161Tb]Tb-DOTA-LM3 (Tb-DOTA-LM3) as a potential therapeutic for somatostatin receptor (SSTR)-positive tumors; and n.c.a. 177Lu-TTM for intra-cavitary immunoradiotherapy in patients with glioblastoma. Ga-DPI-4452 Demonstrates High Tumor Uptake and Superior Detection of ccRCC Compared to Conventional CT Dr. Alina Küper of the Department of Nuclear Medicine at University Hospital Essen in Germany highlighted in an oral presentation the interim results from an independent bicenter retrospective registry evaluating Ga-DPI-4452 PET/CT for imaging 98 patients with suspected or proven ccRCC. In the analysis, Ga-DPI-4452 demonstrated abnormal findings in 91.8% of patients with subsequently confirmed ccRCC. Additionally, Ga-DPI-4452 exhibited high tumor uptake and superior detection efficacy across 153 predefined anatomical regions compared to conventional CT imaging, including in renal primary tumors/recurrence, regional lymph nodes, distant lymph nodes, bone metastases, and visceral metastases. Lower Peptide Mass of [161Tb]Tb-DOTA-LM3 Increases Tumor Absorbed Dose in Metastatic GEP-NETs In an oral presentation, Dr. Julia G. Fricke and Prof. Damian Wild, Physician-Scientists and Researchers in Nuclear Medicine and Theranostics at the University Hospital Basel, Switzerland, shared safety, dosimetry, and preliminary efficacy data from the Phase 0b BETA PLUS study for the SSTR2 antagonist [161Tb]Tb-DOTA-LM3. In the study evaluating dosimetry in 6 patients with metastatic GEP-NETs, a peptide mass-dependent effect was observed, wherein a lower peptide mass (

GlobeNewsWire • Oct 20, 2026

Correction: ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026

Vienna, October 20, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that data supporting its targeted precision oncology portfolio were featured in three oral presentations and one e-poster at the European Association of Nuclear Medicine (EANM) 2026 Congress, held from October 17-21 in Vienna, Austria. The presentations further support ITM's late- and early-stage radiopharmaceutical pipeline, highlighting novel therapeutic and diagnostic candidates across Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), clear cell Renal Cell Carcinoma (ccRCC), and glioblastoma. “The data presented at EANM 2026 underscore the therapeutic potential of our deep targeted radiopharmaceutical pipeline, which leverages different targets, both established and novel radioisotopes, and addresses several difficult-to-treat oncology indications,” said Dr. Celine Wilke, chief medical officer of ITM. “Whether derived from ITM's Phase 3 COMPETE trial or through the valuable insights of independent, investigator-initiated research, this growing evidence base supports the continued development of these novel radiopharmaceuticals across cancers with significant unmet medical need.” Higher Cumulative Tumor Absorbed Dose of 177Lu-edotreotide is Associated with Improved Clinical Response in GEP-NETs Dr. Anthime Flaus of the Hospices Civils de Lyon in Bron, France gave an oral presentation featuring a late-stage dose-response analysis from ITM's Phase 3 COMPETE trial evaluating non-carrier-added (n.c.a.) 177Lu-edotreotide (ITM-11) in patients with Grade 1 or 2 GEP-NETs. The analysis assessed the relationship between tumor cumulative absorbed dose and treatment response in 106 evaluable patients who received 4 treatment cycles of ¹⁷⁷Lu-edotreotide therapy. Higher cumulative tumor absorbed doses were associated with a better Best Overall Response (BOR). The Objective Response Rate (ORR) increased from 12% in the lowest dose quartile (Q1) to 64% in the highest dose quartile (Q4), with three complete responses occurring in patients with a cumulative dose above 86.1 Gy (Q3 and Q4). Cumulative tumor absorbed dose and tumor type were the main predictors of response in multivariate logistic regression models. Lesion-level analysis also identified a statistically significant association between absorbed dose and response. "The dosimetry data from the COMPETE trial offer insights into how tumor absorbed dose correlates with objective response," said Dr. Anthime Flaus, study author and physician at the Hospices Civils de Lyon. "Understanding this dose-response relationship provides important evidence that could potentially support the development of more individualized radiopharmaceutical treatment approaches, with the goal of optimizing patient care and outcomes." Early-Stage Pipeline Data Presented at EANM 2026 The conference also highlighted promising clinical and translational data supporting the further development of other ITM pipeline candidates. These data, derived from independent trials and research initiated by investigators, offer valuable clinical insights to support the further development of ITM candidates currently in Phase 1 trials, including: Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, or CAIX peptide), an investigational diagnostic imaging agent for ccRCC; [161Tb]Tb-DOTA-LM3 (Tb-DOTA-LM3) as a potential therapeutic for somatostatin receptor (SSTR)-positive tumors; and n.c.a. 177Lu-TTM for intra-cavitary immunoradiotherapy in patients with glioblastoma. Ga-DPI-4452 Demonstrates High Tumor Uptake and Superior Detection of ccRCC Compared to Conventional CT Dr. Alina Küper of the Department of Nuclear Medicine at University Hospital Essen in Germany highlighted in an oral presentation the interim results from an independent bicenter retrospective registry evaluating Ga-DPI-4452 PET/CT for imaging 98 patients with suspected or proven ccRCC. In the analysis, Ga-DPI-4452 demonstrated abnormal findings in 91.8% of patients with subsequently confirmed ccRCC. Additionally, Ga-DPI-4452 exhibited high tumor uptake and superior detection efficacy across 153 predefined anatomical regions compared to conventional CT imaging, including in renal primary tumors/recurrence, regional lymph nodes, distant lymph nodes, bone metastases, and visceral metastases. Lower Peptide Mass of [161Tb]Tb-DOTA-LM3 Increases Tumor Absorbed Dose in Metastatic GEP-NETs In an oral presentation, Dr. Julia G. Fricke and Prof. Damian Wild, Physician-Scientists and Researchers in Nuclear Medicine and Theranostics at the University Hospital Basel, Switzerland, shared safety, dosimetry, and preliminary efficacy data from the Phase 0b BETA PLUS study for the SSTR2 antagonist [161Tb]Tb-DOTA-LM3. In the study evaluating dosimetry in 6 patients with metastatic GEP-NETs, a peptide mass-dependent effect was observed, wherein a lower peptide mass (

GlobeNewsWire • Oct 20, 2026

Getting Paid to Extend: The Case for Muni Duration

Treasury's pivot toward long-bond buybacks gives duration buyers their first clear green light in months — and the November midterms may add a second leg. Key takeaways Treasury's decision to at least double 10- to 30-year buybacks is a policy signal, not a technical footnote.

ETF Trends • Aug 30, 2026

ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

Garching / Munich, July 7, 2026 –  ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the publication of its primary result analysis of the Phase 3 COMPETE trial in The Lancet. The clinical data demonstrated that non-carrier-added (n.c.a.) 177Lu-edotreotide (also known as 177Lu-edotreotide or ITM-11) significantly improved progression-free survival (PFS) compared to everolimus in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The publication, titled “[177Lu] Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial,” appeared online on July 2, 2026, and can be accessed via the following link: doi.org/10.1016/S0140-6736(26)00604-5. “COMPETE provides the first high-level evidence directly comparing peptide receptor radionuclide therapy (PRRT) with everolimus, a commonly used systemic standard-of-care therapy, in the treatment of advanced GEP-NETs,” said Jaume Capdevila, MD, PhD, last author, study investigator and senior medical oncologist at Vall d'Hebron University Hospital, Barcelona. “The efficacy and safety results observed with 177 Lu-edotreotide support its consideration as a potential treatment option for appropriate patients, including those whose disease has progressed following somatostatin analog (SSA) therapy.” “Publication of these data in a peer-reviewed journal underscores the scientific importance of the COMPETE study and provides an important forum for dissemination of the results,” added Thomas Walter, MD, PhD, first author, study investigator and professor of gastroenterology, Hospices Civil of Lyon, France. “These findings offer additional insights into PRRT and support 177Lu-edotreotide as a potential therapeutic option in advanced GEP-NETs, where a high unmet need remains.” COMPETE Trial Results The randomized, open-label Phase 3 COMPETE trial evaluated n.c.a. 177Lu-edotreotide versus everolimus in 309 patients with advanced, progressive, Grade 1 or Grade 2 SSTR-positive GEP-NETs across 49 global sites. Patients were randomized 2:1 to receive 177Lu-edotreotide every three months for up to four cycles or everolimus daily for up to 30 months. Patients were not required but permitted to receive SSAs at the investigator's discretion for symptom control only. Overall, 21% of patients received concomitant SSA treatment during the study, with similar proportions receiving SSAs in each treatment arm. Top line results of the trial were initially presented at ENETS 2025 and ESMO 2025. Key findings from the COMPETE trial include:

GlobeNewsWire • Jul 7, 2026

The Muni Brief: Big Flows, Low Drama

Muni ETFs just posted record inflows. Jim Colby on why low volatility, strong risk-adjusted returns, and tax-advantaged yields keep drawing investors in.

ETF Trends • Jun 21, 2026

ITM: Yield Is Most Unattractive Here

VanEck Intermediate Muni ETF tracks intermediate-term, investment-grade municipal bonds, offering tax-free income but only middling returns for the risk taken. ITM's low fees (0.18%) and index-tracking approach provide diversification and lower interest rate risk but limit income potential compared to more selective strategies. Tax-equivalent yields make ITM best suited for investors in higher tax brackets; those below a 24% marginal rate may find better after-tax returns elsewhere.

Seeking Alpha • Nov 3, 2025

Corporate vs. Municipal Bonds: Key Differences Every Investor Should Know

Compare corporate and municipal bonds, including risks, returns, and tax benefits. Learn which bond type fits your investment goals.

ETF Trends • Apr 20, 2025

Municipal Bond Funds: Time To Shine Or Curtain Call?

Municipal bonds are back to offer compelling risk-adjusted opportunities, but future decisions from Washington can either act as a tailwind or headwind. Municipal bond funds saw net inflows during 2024, first annual inflow since 2021—which was a record year. 2024 was a record year in municipal bond issuance. With attractive yields, the market may start to pay more attention to tax-equivalent yield advantages offered through municipal debt.

Seeking Alpha • Mar 13, 2025

Municipal Fixed Income: Shelter From The Storm?

Specific to the muni market, perhaps the biggest surprise this year has been new issue supply that is running well ahead of expectations, up roughly 40% from last year. We think this increased summer issuance is likely the result of deals getting pulled forward, as issuers may be cautious about coming to market later in the fall ahead of what is likely to be an uncertain U.S. political climate. While municipal credit quality has already peaked, it is entering this period of moderating economic growth from a position of strength.

Seeking Alpha • Aug 26, 2024

See a Fork in the Road?

By James Colby, Portfolio Manager and Strategist, Municipal Bonds Barclays sees stable municipal yields due to supply, while BofA predicts lower rates from Quantitative Tapering and economic softening. Yogi Berra said, “pick it up”.

ETF Trends • May 25, 2024